Senior Director, Patient Preference Elicitation
Pfizer, Inc.
Dr. Brett Hauber is a Senior Director and Patient Preference Elicitation Expert on the Global Medical Impact Assessment Team at Pfizer and Affiliate Associate Professor in the CHOICE Institute of the University of Washington School of Pharmacy. Brett has more than 20 years of academic, research, and government experience in health and environmental economics, structured benefit-risk analysis and preference elicitation. He was the principal investigator for developing the catalog of patient preference methods developed by the Medical Device Innovation Consortium (MDIC). He is currently Co-Chair for Benefit-Risk Assessment in the Benefit-Risk Assessment, Communication, and Evaluation (BRACE) Special Interest Group (SIG) of the International Society for Pharmacoepidemiology (ISPE). He previously served as chair of the Conjoint Analysis Good Research Practices Task Force of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) that developed the report on Good Research Practices in Statistical Methods for the Analysis of Discrete-Choice Experiments and was a member of the ISPOR task force that developed the ISPOR Checklist for Good Research Practices in Conjoint Analysis. He was the lead investigator on a collaborative effort by MDIC, the Center for Devices and Radiological Health of the Food and Drug Administration (FDA), The Michael J Fox Foundation for Parkinson’s Research, and the Massachusetts Institute of Technology to develop a patient-centered design for clinical trials of devices to treat Parkinson’s disease. Dr. Hauber was currently a member of the Scientific Advisory Board for IMI-PREFER and has submitted multiple patient preference studies to regulators to support decisions reagrding endpoint selection, performance criteria, clinical trial design, and benefit-risk assessment. Prior to joining Pfizer, Brett was a Senior Fellow at RTI-Health Solutions.
Disclosure information not submitted.